Editor's note: The application of PET/CT technology in the diagnosis of lung tumors has greatly improved the diagnostic accuracy of lung cancer and other diseases, and has become an indispensable part of modern medical imaging technology. With the continuous advancement of technology and the deepening of applications, PET/CT is expected to play a greater role in the diagnosis and treatment of lung tumors in the future.
Professor Li Gaofeng of Yunnan Provincial Cancer Hospital is the executive editor-in-chief of this issue of "Expert Group Draft", who will share with Professor Liu Chao the innovative application of PET/CT technology in the field of lung tumor diagnosis in the fourth issue, providing more references for doctors and patients.
About the Speaker
Li Gaofeng
Vice President of Yunnan Hospital, Peking University Cancer Hospital (Yunnan Provincial Cancer Hospital, Third Affiliated Hospital of Kunming Medical University).
Doctoral supervisor, postdoctoral cooperative supervisor, second-level professor, chief physician
Yunnan Health Guard, Provincial Association for Science and Technology Outstanding Society Worker
President of Yunnan Translational Medicine Society
Vice Chairman of Yunnan Anti-Cancer Association
Chairman of the Thoracic and Cardiovascular Surgery Branch of Yunnan Medical Association
Chairman of the Minimally Invasive Treatment Committee of Thoracic Tumors of Yunnan Anti-Cancer Association
Executive Director of Yunnan Preventive Medicine Association and Chairman of Lung Cancer Professional Committee
Member of the International Association for the Study of Lung Cancer
He is a member of the Standing Committee of the Mediastinal Tumor Professional Committee of the Chinese Anti-Cancer Association
Member of the Thoracoscopic Surgery Group of the Thoracic and Cardiovascular Surgery Branch of the Chinese Medical Association
Member of the Working Committee of the Medical Consortium of the Chinese Hospital Association
Member of the National Lung Cancer MDT Expert Committee
National outstanding scientific and technological worker, expert enjoying special allowance of the State Council
Winner of the National May Day Labor Medal, Yunnan Provincial Medical Leading Talent, Yunling Famous Doctor
Yunnan Province has outstanding professional and technical personnel with outstanding contributions and experts contacted by the provincial party committee
Liu Chao
Deputy Chief Physician of the Department of Nuclear Medicine, Yunnan Hospital, Peking University Cancer Hospital (Yunnan Provincial Cancer Hospital, Third Affiliated Hospital of Kunming Medical University).
Master's supervisor, doctor of oncology
Member of the National Youth Committee of the Nuclear Medicine Branch of the Chinese Medical Association
Leader of the imaging team of Yunnan Provincial Nuclear Medicine Professional Medical Quality Control Center
Secretary-General of the Nuclear Medicine Committee of the Yunnan Branch of the Chinese Medical Association
High-level medical reserve talents in Yunnan Province
Kunming Medical University "Excellent Teacher of Three Educations"
Excellent secretary of Yunnan Provincial Medical Association
Phase IV: New Perspectives in Lung Tumor Diagnosis: Innovative Application of PET/CT Technology
◾ Li Gaofeng, Liu Chao, Yunnan Provincial Cancer Hospital
PET/CT is an advanced medical imaging technique that combines positron emission tomography (PET) and computed tomography (CT). This technique provides important information about the structure and function of the lungs by detecting the distribution and metabolic activity of radiolabeled glucose in the body. PET/CT is becoming increasingly important in diagnosing pulmonary nodules. Traditional imaging techniques, such as chest x-ray or CT scans, provide morphological information about the nodules, but are often limited in distinguishing between benign and malignant nodules. PET/CT combines the advantages of metabolic imaging of PET with the advantages of high-resolution anatomical imaging of CT, which can more accurately identify and classify pulmonary nodules. By measuring the metabolic activity in pulmonary nodules, PET/CT can help identify which nodules are more likely to be malignant, thus providing an important basis for subsequent clinical decisions. With the continuous advancement of medical imaging technology, PET/CT has become more and more widely used in the diagnosis of pulmonary nodules, and has become an indispensable tool in the evaluation and management of modern pulmonary nodules.
1. Accurately identify the benign and malignant pulmonary nodules
Pulmonary nodules are small pieces of abnormal tissue in the lungs that vary in size, shape, and density. Lung nodules can be benign in nature, such as those caused by infection or inflammation, or malignant, such as lung cancer. Correctly diagnosing the nature of these nodules is essential to determine the best treatment options. PET/CT plays a key role in this process. One of the most critical challenges in the diagnosis of pulmonary nodules is to accurately distinguish between benign and malignant nodules. The sensitivity and specificity of PET/CT have varied across studies, but most studies have shown a high accuracy in differentiating benign from malignant pulmonary nodules. In particular, the use of PET/CT is particularly important for solitary pulmonary nodules with nodules between 8 mm and 30 mm in size.
PET/CT offers a solution to this dilemma in its unique way of measuring the activity of glucose metabolism in pulmonary nodules. Tumour cells typically consume more glucose than normal cells because they require more energy to grow quickly. This increase in metabolic activity is shown in PET/CT imaging as high glucose uptake, helping doctors distinguish between benign and malignant nodules in the lungs. This technique not only helps to avoid unnecessary invasive testing of some benign nodules, but also ensures that potentially malignant nodules are identified in a timely manner, allowing treatment to begin early. With its high sensitivity and specificity, PET/CT has become an important tool in the evaluation of pulmonary nodules, supporting individualized clinical decision-making. By considering the results of PET/CT and the patient's specific situation, doctors can provide patients with more accurate diagnosis, treatment planning, and prognostic assessment. The application of PET/CT in distinguishing benign and malignant pulmonary nodules not only improves the accuracy of diagnosis, but also provides strong support for patient management and treatment, which is an indispensable part of the evaluation of pulmonary nodules.
2. Accurate assessment of lung cancer stages
Early diagnosis and accurate staging of lung cancer are essential for developing treatment plans and predicting disease prognosis. PET/CT plays a key role in the assessment of all stages of lung cancer, especially when determining whether the cancer has spread to other parts of the lungs.
In the early diagnosis of lung cancer, PET/CT can help identify small, malignant nodules in the lungs that can be difficult to detect on a conventional CT scan. By assessing the metabolic activity of lung nodules, PET/CT can provide more accurate information than traditional imaging techniques, helping to detect lung cancer at an early stage. The staging of lung cancer involves determining the size of the cancer, whether it has invaded surrounding tissues, and whether distant metastases are present. PET/CT is especially important in this process because it provides both metabolic information and anatomical location of the tumor, helping doctors assess local spread and distant metastasis of lung cancer. PET/CT is more sensitive and specific than traditional CT scans and magnetic resonance imaging (MRI) in detecting lymph node metastases and distant organ metastases.
PET/CT can also be used to monitor lung cancer patients' response to treatment during treatment. By comparing the results of the scans before and after treatment, it is possible to assess whether the metabolic activity of the tumor is reduced, so as to determine whether the treatment is effective. This is useful for adjusting treatment regimens and predicting treatment outcomes. For lung cancer patients, there is still a risk of recurrence even after successful treatment. PET/CT has shown a high degree of sensitivity in monitoring recurrence, enabling early detection of signs of recurrence and ensuring that patients can receive further treatment in a timely manner. Monitoring for recurrence after lung cancer treatment is a crucial part of the process to help detect the recurrence of the disease early and prompt appropriate treatment measures.
PET/CT has shown great value in the detection of recurrent lung cancer, as it can sensitively identify areas of increased metabolic activity, which are often early signs of recurrence. Compared with traditional imaging techniques, PET/CT has higher sensitivity and specificity in detecting lung cancer recurrence. It is able to distinguish between active tumor tissue and inactive scar tissue or other non-neoplastic lesions, thereby reducing the risk of misdiagnosis and missed diagnosis. PET/CT can detect tumor recurrence through changes in metabolic activity before clinical symptoms appear, providing patients with the opportunity for early treatment. This has improved the survival rate and quality of life of patients to some extent. Treatment options for recurrent lung cancer need to be tailored to the location, size, and nature of the recurrence. PET/CT provides detailed information that allows doctors to develop a more individualized and precise treatment plan, including surgery, radiation therapy, chemotherapy, or other targeted therapies.
PET/CT can also be used to evaluate the response to treatment and monitor changes in the metabolic activity of the tumor after treatment of recurrent lung cancer. This provides an important basis for judging whether treatment strategies need to be adjusted. As an efficient imaging technology, PET/CT plays an important role in the early detection of lung cancer recurrence, treatment decision support, and treatment effect evaluation. The accuracy and reliability of PET/CT in the diagnosis, staging, treatment response assessment and recurrence monitoring of lung cancer is one of the key factors for its widespread application. This imaging technique combines the advantages of positron emission tomography (PET) and computed tomography (CT) to provide metabolic and anatomical information about the tumor, thereby greatly improving the accuracy of diagnosis.
3. Limitations and challenges
Although PET/CT plays an important role in diagnosing lung cancer, it still has some limitations and shortcomings. For lesions smaller than a certain size (usually less than 5 mm), the sensitivity of PET/CT is reduced, which may lead to missed diagnosis of small nodules. PET/CT measures high glucose uptake, while certain non-malignant conditions such as infection and inflammation may also exhibit high glucose uptake, leading to false-positive results. Differentiating between malignant and benign processes by PET/CT alone can be challenging and needs to be used in conjunction with clinical findings and other diagnostic approaches. Due to the inhomogeneity of 18F-fluorodeoxyglucose uptake and its limitation of spatial resolution, tumor boundaries on PET images may appear unclear, which complicates accurate tumor definition and staging.
Despite its advantages, PET/CT may limit its use due to its high cost and limited availability, especially in resource-limited settings. The economic impact of the widespread use of PET/CT remains an important factor for healthcare systems to consider.
In conclusion, PET/CT plays an important role in the diagnosis of lung tumors due to its high accuracy and reliability. It can not only provide key information for disease diagnosis, but also provide an important basis for the formulation and adjustment of treatment plans, helping to achieve personalized medicine. At the same time, doctors and patients need to be aware of their limitations and consider a variety of information to make diagnosis and treatment decisions.
Editor-in-Chief's comments
This article discusses the clinical application value of PET/CT in lung tumors. PET/CT technology can provide important information about lung structure and function at the same time, especially in distinguishing benign and malignant lung nodules, as well as early diagnosis, staging, treatment response assessment and recurrence monitoring of lung cancer. Although PET/CT technology has significant advantages in the diagnosis of lung tumors, the article also objectively analyzes its limitations. These limitations suggest that physicians need to be cautious in interpreting PET/CT results in conjunction with other clinical information and diagnostic approaches to achieve optimal outcomes. The article is clearly structured and logically rigorous, which not only demonstrates the important application value of PET/CT technology, but also frankly discusses its challenges and limitations, providing a comprehensive and balanced perspective for doctors and patients to promote its rational application in clinical practice.
Copyright Notice
The copyright of this article belongs to Yiyue Hui. Welcome to forward and share, if any other media needs to reprint or quote the copyrighted content of this website, it must be authorized, and indicate "Transferred from: Yiyuehui" in a conspicuous position.